Immunotherapy : Episode 9

Video

Episode 9 - The Payer Approach to Immunotherapy

In this segment, the panelists explain how coverage policies vary by payer, and explore the factors that affect the costs associated with different immunotherapy agents.

Michael Kolodziej, MD, discusses how Aetna reviews evidence and takes several factors into account when making payer decisions about supporting cancer research, and explains that different organizations have different processes. Jeffrey Weber, MD, PhD, continues the conversation with an explanation of how different immunotherapy agents have different dosage and administration requirements, which affect overall costs.

Addressing cost differentials and coverage policy inconsistencies is important because what is covered by payers directly impacts the types of treatments that are recommended to patients. As concluded by Daniel J. George, MD, providers want to be able to recommend a clinical trial or other treatment modality in situations where standard therapy is not likely to be effective for the patient.


Related Videos
Casey Koch, PharmD, sitting for a video interview
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Kimlin Tam Ashing
Jaime Almandoz, MD, MBA
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Galen Shearn-Nance, BS
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo